Caris Life Sciences has launched the enhanced Caris Assure, a new evolution in liquid biopsy technology offering deeper molecular insights for precision oncology.

Caris Life Sciences has applied for authorization from New York State to use its innovative blood-based molecular profiling test, Caris Assure, which analyzes thousands of genes.

Caris Life Sciences has published a pivotal study demonstrating the effectiveness of its blood-based assay for diagnosing multiple cancers, showcasing advances in early detection and therapy selection.

A significant study published by Caris Life Sciences showcases how their Caris Assure™ technology enhances cancer diagnosis by distinguishing between tumor and clonal hematopoiesis mutations.